Endovascular Today
VerifiedMagazine
Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurointerventionists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.
Endovascular Today is published 12 times per year and also offers a free biweekly eNewsletter, advising of recent FDA approvals, clinical trial updates, Medicare coverage news, and new product launches. Please visit our subscriptions page for more information on receiving Endovascular Today.
Actions
Media Outlet details
| Scope | Trade/B2B, Consumer |
|---|---|
| Language | English |
| Country | United States of America |
Similarweb UVM
|
Request pricing |
Comscore UVM
|
Request pricing |
| Frequency | Monthly |
Recent Articles
Search ArticlesVS3 System Receives FDA Breakthrough Device Designation to Treat Debilitating Pulsatile Tinnitus
KEY TAKEAWAYS The FDA granted Breakthrough Device designation to the investigational VS3 system. The designation was based on evidence indicating the system has the potential to resolve pulsatile tinnitus associated with venous sinus stenosis. The self-expanding device is designed to conform to the venous sinus and treat intrinsic and extrinsic stenoses.
iVascular’s Amber Liquid Embolic Evaluated in Premarket OPAL Study
KEY TAKEAWAYS Phase 2 OPAL data included 70 patients treated with iVascular’s Amber liquid embolic. Total occlusion was achieved in 98.6% of patients, with no microcatheter entrapment or material migration reported. OPAL is a prospective, multicenter premarket study conducted at 11 centers in Spain. September 29, 2026—iVascular announced new phase 2 data from the OPAL study of Amber, the company’s liquid embolic.
Embolization Shows Favorable Results in High-Grade Kidney Injuries
KEY TAKEAWAYS In findings published in JVIR, embolization was associated with lower in-hospital mortality and acute kidney injury rates than nephrectomy in initially stable patients with grade III-V renal trauma. The registry analysis included 849 patients treated with embolization or nephrectomy between 2017 and 2022. Lead investigator, Dr. Waseem Wahood, advised that prospective studies are needed to validate the findings and further assess a renal-preservation strategy.
CIRSE Initiates ORACLE and RESCUE Studies of Endovascular Interventions for CLTI
KEY TAKEAWAYS CIRSE has initiated patient enrollment in two prospective observational studies evaluating endovascular interventions for patients with CLTI: ORACLE and RESCUE Both studies are scientifically sponsored by CIRSE and funded by Abbott Vascular International BV through its investigator-sponsored study program ORACLE is evaluating orbital atherectomy with the Stealth 360 in calcified femoropopliteal and infrapopliteal lesions; RESCUE is studying the Esprit BTK everolimus-eluting...
iVascular’s iCover Stent for Treatment of Iliac Lesions Evaluated in 1-Year ILICO Results
KEY TAKEAWAYS The ILICO study evaluated iVascular’s iCover covered stent in 232 patients with de novo iliac atherosclerotic lesions. At 1 year, primary patency was 90.3%, and freedom from target lesion revascularization was 96.7%. The observational study included complex disease, with 30% TASC C or D lesions and 31% complete occlusions.
Route 92 Medical’s FreeClimb 46 Catheter with Tenzing 4 Cleared by FDA
KEY TAKEAWAYS FDA 510(k) clearance granted for Route 92 Medical’s FreeClimb 46 catheter with Tenzing 4 for neurovascular access. The integrated system extends the company’s catheter portfolio to smaller and more distal vessels. The FreeClimb 46 joins the company’s FreeClimb 54, 70, and 88 systems. September 28, 2026—Route 92 Medical, Inc. announced FDA 510(k) clearance for the FreeClimb 46 catheter with Tenzing 4.
Rapid Medical’s Tigertriever 17 Ultra Receives CE Mark Approval for Stroke Treatment
KEY TAKEAWAYS Rapid Medical’s Tigertriever 17 Ultra has received CE Mark approval and is commercially available in Europe. The adjustable clot retriever is intended for thrombus removal from a large intracranial vessel within 8 hours of ischemic stroke symptom onset. The new device is 45% longer than the standard Tigertriever 17, providing a larger clot capture area.
Optimizing Patient Selection for the DETOUR™ System
Amit Dwivedi, MD, FACS Professor and Division Chief of Vascular Surgery University of Louisville Louisville, Kentucky Disclosures: Paid consultant of Endologix. Has your patient selection evolved since your first case with the DETOUR™ System (Endologix)? Yes, my approach to patient selection has evolved since I first started using the DETOUR System.
PAD Endpoints From ATK to BTK: Measuring What Matters
Peripheral artery disease (PAD) affects more than 230 million people worldwide and is a major cause of disability, cardiovascular events, and limb loss. Over the past 3 decades, advances in endovascular therapy have transformed the management of PAD, allowing treatment of increasingly complex lesions.1,2 These endovascular approaches will continue to advance.